Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.50 |
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13958278 | 0.88 | DYRK1A (0.50) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL22743382 | 0.79 | DYRK1A (0.55) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL29600967 | 0.79 | KDM4E (1.00) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL3874542 | 0.79 | KDM4E (1.00) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL30974636 | 0.79 | DYRK1A (0.55) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL4448233 | 0.77 | DYRK1A (0.61) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL29366180 | 0.76 | MAOA (0.76) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL124175 | 0.76 | MAOA (0.76) | KDM4EALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL18327130 | 0.75 | DYRK1A (0.69) | MAPTDYRK1AESR2ESR1KMT2A | |
| SCHEMBL2766972 | 0.74 | KDM4E (0.59) | KDM4EALDH1A1LMNAHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | WYETH (US) | 2006-01-05 | — | — | US | claimed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1761513-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | Wyeth (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006007503-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | WYETH (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | ESR1, ESRRA, ESR2 | KDM4E 859/4885ALDH1A1 3218/4885LMNA 3527/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | KDM4E 1534/4885ALDH1A1 1461/4885LMNA 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.